Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts ≥ 200 cells/μl
- 12 May 2006
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (8) , 1117-1123
- https://doi.org/10.1097/01.aids.0000226951.49353.ed
Abstract
Background: Baseline plasma HIV RNA levels > 100 000 copies/ml have been associated with elevated mortality rates after the initiation of HAART. There is uncertainty regarding the optimal strategy for patients with high plasma HIV RNA but CD4 cell count ≥ 200 cells/μl. Objective: To evaluate the impact of baseline plasma HIV RNA on survival among patients with CD4 cell counts ≥ 200 cells/μl. Methods: Patients were stratified by plasma HIV RNA, CD4 cell count and adherence level. Mortality rates were evaluated using Kaplan–Meier methods and Cox regression. Results: Among 1166 patients initiating HAART with a CD4 cell count ≥ 200 cells/μl, a baseline HIV RNA ≥ 100 000 copies/ml was statistically associated with elevated mortality among non-adherent patients (log-rank P = 0.032), but not for adherent patients (log-rank P = 0.690). In a multivariate Cox model comparing patients with a baseline CD4 cell count ≥ 200 cells/μl and a baseline plasma HIV RNA < 100 000 copies/ml, the mortality rate was statistically similar among patients with a baseline CD4 cell count ≥ 200 cells/μl and a baseline plasma HIV RNA ≥ 100 000 copies/ml (relative hazard, 1.21; 95% confidence interval, 0.89–1.65; P = 0.232). Conclusion: HIV RNA ≥ 100 000 copies/ml was only associated with mortality among HIV-infected patients initiating HAART with CD4 cell counts ≥ 200 cells/μl if the patients were non-adherent.Keywords
This publication has 32 references indexed in Scilit:
- Treatment for Adult HIV InfectionJAMA, 2004
- Treatment of antiretroviral-drug-resistant HIV-1 infectionThe Lancet, 2003
- Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/LAnnals of Internal Medicine, 2003
- Initiation of Highly Active Antiretroviral Therapy at CD4+T Lymphocyte Counts of >350 cells/mm3: Disease Progression, Treatment Durability, and Drug ToxicityClinical Infectious Diseases, 2003
- Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studiesThe Lancet, 2002
- Changes in Mitochondrial DNA as a Marker of Nucleoside Toxicity in HIV-Infected PatientsNew England Journal of Medicine, 2002
- Rates of Disease Progression by Baseline CD4 Cell Count and Viral Load After Initiating Triple-Drug TherapyJAMA, 2001
- When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA studyAIDS, 2001
- Antiretroviral treatment in 1998The Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997